第十一批国家药品集采文件发布

Core Viewpoint - The National Healthcare Security Administration of China announced the 11th batch of centralized drug procurement, including 55 drug varieties, with bidding scheduled for October 21 in Shanghai. The procurement process emphasizes principles such as "stability in clinical use, quality assurance, prevention of collusion, and countering excessive competition" [1] Group 1: Procurement Process Changes - The new procurement scheme allows medical institutions to report quantities based on specific brands rather than just generic names, aligning supply with clinical needs more effectively [1] - The procurement process introduces stricter quality control requirements for participating companies, mandating at least two years of production experience for similar formulations and compliance with GMP standards [1] Group 2: Selection Criteria Adjustments - The selection rules have been significantly revised to avoid solely relying on the lowest bid, introducing a benchmark price that requires participating companies to submit bids at or above the higher of 50% of the average comparable unit price or the lowest comparable unit price [1]